General
Preferred name
GLYBURIDE
Synonyms
glibenclamide ()
Glybenclamide ()
Glibenclamide potassium salt ()
Glyburide10238-21-8 ()
Glyburide potassium salt ()
Glyburide (Glibenclamide) ()
Amglidia ()
U-26,452 ()
Lederglib ()
Glibenclamide ()
Glynase ()
HB 419 ()
Glibenclamidum ()
Euglucon ()
Calabren ()
Diabetamide 2.5 ()
Libanil ()
HB-419 ()
Glyburide (micronized) ()
Gliken ()
Semi-daonil ()
U-26452 ()
Glynase Prestab ()
Cirara ()
U-26,45 ()
NSC-759618 ()
Malix ()
Micronase ()
Daonil ()
Glibenclamida ()
Diabeta ()
Diabetamide 5 ()
Glyburide (potassium salt) ()
Glyburide-d3 ()
P&D ID
PD000061
CAS
10238-21-8
52169-36-5
1219803-02-7
Tags
available
probe
drug
Approved by
EMA
FDA
First approval
1984
Drug indication
Diabetic complication
Stroke
Antidiabetic
Drug Status
approved
Max Phase
4.0
Probe info
Probe selectivity
protein-selective
Probe type
P&D approved
experimental probe
Probe sources
Chemical Probes.org
High-quality chemical probes
Probe targets
Structure
Probe scores
P&D probe-likeness score
[[ v.score ]]%
Structure formats
[[ format ]]
[[ compound[format === 'MOL' ? 'molblock' : format.toLowerCase()] ]]
Description
(extracted from source data)
DESCRIPTION A sulfonylurea family drug inhibiting sulfonylurea receptor 1 (ABCC8)/Kir6.2 (KCNJ11)
ROE Glyburide is excreted as metabolites in the bile and urine, approximately 50% by each route.; This dual excretory pathway is qualitatively different from that of other sulfonylureas, which are excreted primarily in the urine.
DESCRIPTION A sulfonylurea family drug inhibiting sulfonylurea receptor 1 (ABCC8)/Kir6.2 (KCNJ11). Glibenclamide induced blockade of SUR1-TRPM4 channels reduces inflammatory markers and improves clinical symptoms in mouse experimental autoimmune encephalomyelitis (EAE), and may be of relevance in multiple sclerosis as SUR1-TRPM4-expressing lesions from MS provide a potentially disease modiifying target . (GtoPdb)
COMMENT Serum Glibenclamide in Diabetic Patients, and Influence of Food on the Kinetics and Effects of Glibenclamide is not useful to include for consideration as chemical probe (although is useful to list in extra info for use as clinical biomarker). It would have been more helpful to provide the refs that the data shown were extracted from and these should definitely be listed alongside the probe at the top. The mode of action of these sulfonyl ureas is clearly complex and its understanding has followed the appreciation of their clinical utility. This molecule is clearly able to regulate several ABC transporters by modulation of the K-ATP channels – but there is considerable discussion (e.g. doi: 10.1074/jbc.M110.155200) of block of other related channels – e.g. CFTR. There is clear evidence that glibenclamide is a wide spectrum KATP blocker [https://pubs.acs.org/doi/pdf/10.1021/jm970762d; European Journal of Medicinal Chemistry 39 (2004) 835–847; Bioorganic & Medicinal Chemistry 11 (2003) 2099–2113) and that different in vivo responses are seen with other related compounds which have a narrower spectrum of KATP block (J. Med. Chem. 2001, 44, 1085-1098). CFTR is inhibited by glibenclamide and less potently by a few other KATP channel blockers and openers (J Gen. Physiol., 100: 573-591, 1992). Glibenclamide also inhibits MRP1 (Br. J. Pharmacol., 132: 778-784, 2001) and P-gp (Pflugers. Arch., 437: 652-660, 1999), and it appears to be a substrate of the latter. Therefore, this molecule is a useful blocker of the K-ATP channels (i.e. those containing 4 Kir6.x and 4 SUR subunits) – but there is limited information about the molecular mechanism of differential effects seen in different tissue/organelle type and additional evidence of blockade of other ABC transporters (CFTR, MRP1, PGP). This is clearly a good probe candidate but from a single publication so far. The best identifier is https://pubchem.ncbi.nlm.nih.gov/compound/103828029.  The two melatonic receptor human paralogues  are well studied pharmacologically so additional compounds and controls are also available for comparative testing  A curated selected listing of these can be found here  https://www.guidetopharmacology.org/GRAC/ObjectDisplayForward?objectId=288 Jun 2 2020 - 1:01pm
MOA Inhibitor (Chemical Probes.org)
DESCRIPTION Non-competitive NMDA antagonist; acts at ion channel site (Tocris Bioactive Compound Library)
DESCRIPTION Kir6 (KATP) channel blocker (Tocriscreen Plus)
DESCRIPTION K+ channel blocker (KATP) (Tocriscreen Total)
DESCRIPTION Antidiabetic agent which blocks pancreatic ATP-dependent K+ channels resulting in an increase in intracellular Ca2+ and consequent insulin secretion (LOPAC library)
DESCRIPTION Glyburide is a sulfonylurea receptor 1 (SUR1) inhibitor linked to ATP-sensitive potassium channel Kir6.2 with an IC50 value of 4.3 nM. (BOC Sciences Bioactive Compounds)
Cell lines
2
Organisms
6
Compound Sets
41
AdooQ Bioactive Compound Library
A10433
Axon Medchem Screening Library
2064
BOC Sciences Bioactive Compounds
glyburide-potassium-salt-cas-52169-36-5-334073
Cayman Chemical Bioactives
25740
15009
ChEMBL Approved Drugs
CHEMBL472
ChEMBL Drugs
CHEMBL472
Chemical Probes.org
glyburide
Concise Guide to Pharmacology 2017/18
2414
Concise Guide to Pharmacology 2019/20
2414
Concise Guide to Pharmacology 2021/22
2414
Concise Guide to Pharmacology 2023/24
2414
CZ-OPENSCREEN Bioactive Library
Drug Repurposing Hub
DrugBank
DB01016
DrugBank Approved Drugs
DB01016
DrugCentral
1314
DrugCentral Approved Drugs
1314
DrugMAP
DM8JXPZ
DrugMAP Approved Drugs
DM8JXPZ
DrugMatrix
Enamine BioReference Compounds
EU-OPENSCREEN Bioactive Compound Library
EOS101572
Guide to Pharmacology
2414
High-quality chemical probes
PD000061
JUMP-Target 1 Compound Set
3488
LOPAC library
LSP-MoA library (Laboratory of Systems Pharmacology)
CHEMBL472
Mcule NIBR MoA Box Subset
MCULE-2351642942
MedChem Express Bioactive Compound Library
HY-15206
NCATS Inxight Approved Drugs
SX6K58TVWC
NIH Clinical Collections (NCC)
Novartis Chemogenetic Library (NIBR MoA Box)
NPC Screening Collection
Prestwick Chemical Library
ReFrame library
Selleckchem Bioactive Compound Library
Glyburide(Diabeta)
TargetMol Bioactive Compound Library
T1634
The Spectrum Collection
Tocris Bioactive Compound Library
0911
Tocriscreen Plus
0911
Tocriscreen Total
External IDs
65
Properties
(calculated by RDKit )
Molecular Weight
493.14
Hydrogen Bond Acceptors
5
Hydrogen Bond Donors
3
Rotatable Bonds
8
Ring Count
3
Aromatic Ring Count
2
cLogP
3.64
TPSA
113.6
Fraction CSP3
0.39
Chiral centers
0.0
Largest ring
6.0
QED
0.52
Structural alerts
0
No structural alerts detected
Related compounds
Custom attributes
(extracted from source data)
Target Type
Ion Channels
Selectivity
ATP-dependent
Pathway
Membrane Transporter/Ion Channel
Autophagy
Metabolic Enzyme/Protease
Target
Bile salt export pump
Potassium Channel
ABCA1, ABCB11, ABCC8, ABCC9, CFTR, CPT1A, KCNJ1, KCNJ11, KCNJ5, KCNJ8, SLCO2B1
KATP channel blocker
SLCO2B1
CFTR
Mitochondrial Metabolism
P-glycoprotein
ABCC8, KCNJ11
Primary Target
Inward Rectifier Potassium (Kir) Channels
MOA
Blocker
K(ATP) Channel Blockers
ATP channel blocker, insulin secretagogue, sulfonylurea
Member status
member
Indication
diabetes mellitus, hyperglycemia
Target subclass
Potassium channel
Potassium channel, Potassium channel
Target class
Ion channel
Ion Channel, Ion Channel
Orthogonal probe
Repaglinide
Therapeutic Class
Hypoglycemic Agents
Source data